We caught up with Prof. John E Harris (University of Massachusetts Medical School, MA, USA) to discuss the safety and efficacy results from a Phase 2 study (NCT03099304) investigating ruxolitinib cream, a JAK1/ JAK2 inhibitor, in adults with vitiligo.
His abstract entitled ‘Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: 104-Week Data From a Phase 2 Study‘ was presented at the AAD VMX, 23-25 April 2021.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.Â
Questions
- What is the rationale for the use of ruxolitinib cream in the treatment of adults with vitiligo? (0:05)
- What was the design of the Phase 2 study, and what did the primary data analysis teach us? (1:19)
- How did the 104-week data compare to that at 52 weeks in terms of the efficacy endpoints? (2:02)
- What was the safety profile of treatment with ruxolitinib cream over 104 weeks? (2:40)
- What is the clinical significance of these findings? (3:32)
Disclosures: Prof. John E Harris has acted and a consultant and investigator for Pfizer, Genzyme/ Sanofi, Incyte, Rheos Medicines, Sun Pharmaceutical, LEO Pharma, Villaris Therapeutics, Dermavant and TeVido BioDevices; a consultant for AbbVie, Janssen, Almirall, Methuselah Health, Pandion, AnaptysBio, Avita, NIRA Biosciences, Admirx, Granular Therapeutics and Platelet BioGenesis; has Equity in TeVido Biodevices, Rheos, Villaris Therapeutics, NIRA Biosciences and is Founder of Villaris Therapeutics and NIRA Biosciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
